These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 19279350)

  • 21. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
    Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
    Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M; Berg T
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract]   [Full Text] [Related]  

  • 23. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
    Kowala-Piaskowska A; Figlerowicz M; Mozer-Lisewska I; Słuzewski W
    Przegl Epidemiol; 2005; 59(2):491-8. PubMed ID: 16190558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
    Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
    Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical characterization and peculiarities of the clinical course of low-activity hepatitis C].
    Karpov SIu; Krel' PE
    Klin Med (Mosk); 2005; 83(1):14-9. PubMed ID: 15759484
    [No Abstract]   [Full Text] [Related]  

  • 28. Chronic hepatitis C virus infection.
    Flamm SL
    JAMA; 2003 May; 289(18):2413-7. PubMed ID: 12746366
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1.
    Brandão C; Barone A; Carrilho F; Silva A; Patelli M; Caramori C; Focaccia R; Pereira L; Pedroso M; Tatsch F; Pessoa M;
    J Viral Hepat; 2006 Aug; 13(8):552-9. PubMed ID: 16901286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The substantial role of initial ribavirin dose on the response to peginterferon alpha/ribavirin therapy in patients with genotype 1b chronic hepatitis C.
    Dai CY; Huang CF; Chuang WL; Huang JF; Yu ML
    Am J Gastroenterol; 2009 Sep; 104(9):2358-9. PubMed ID: 19727098
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
    Shiffman ML; Ghany MG; Morgan TR; Wright EC; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Gretch DR
    Gastroenterology; 2007 Jan; 132(1):103-12. PubMed ID: 17241864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical management of liver transplant recipients for hepatitis C.
    Saab S; Busuttil RW
    Minerva Chir; 2003 Aug; 58(4):479-89. PubMed ID: 14603160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
    Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
    Masarone M; Persico M
    Expert Rev Anti Infect Ther; 2011 May; 9(5):535-43. PubMed ID: 21609265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.
    Dumortier J; Ducos E; Scoazec JY; Chevallier P; Boillot O; Gagnieu MC
    J Viral Hepat; 2006 Aug; 13(8):538-43. PubMed ID: 16901284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study.
    da Silva LC; Bassit L; Ono-Nita SK; Pinho JR; Nishiya A; Madruga CL; Carrilho FJ
    J Gastroenterol; 2002; 37(9):732-6. PubMed ID: 12375147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 39. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
    Inoue K; Sekiyama K; Yamada M; Watanabe T; Yasuda H; Yoshiba M
    J Gastroenterol; 2003; 38(6):567-72. PubMed ID: 12825133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.